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Abstract 
 The purpose of this study is to determine whether organ sparing and target coverage can be simultaneously 
maintained for pencil beam scanning (PBS) proton therapy treatment of thoracic tumors in the presence of motion, stopping 
power uncertainties and patient setup variations. Ten consecutive patients that were previously treated with proton therapy to 
66.6/1.8 Gy (RBE) using double scattering (DS) were replanned with PBS. Minimum and maximum intensity images from 
4DCT were used to introduce flexible smearing in the determination of the beam specific PTV (BSPTV). Datasets from eight 
 2 / 20 
 
4DCT phases, using ±3% uncertainty in stopping power, and ±3 mm uncertainty in patient setup in each direction were used 
to create 8×12×10=960 PBS plans for the evaluation of ten patients. Plans were normalized to provide identical coverage 
between DS and PBS. The average lung V20, V5, and mean doses were reduced from 29.0%, 35.0%, and 16.4 Gy with DS to 
24.6%, 30.6%, and 14.1 Gy with PBS, respectively. The average heart V30 and V45 were reduced from 10.4% and 7.5% in 
DS to 8.1% and 5.4% for PBS, respectively. Furthermore, the maximum spinal cord, esophagus and heart dose were 
decreased from 37.1 Gy, 71.7 Gy and 69.2 Gy with DS to 31.3 Gy, 67.9 Gy and 64.6 Gy with PBS. The conformity index 
(CI), homogeneity index (HI), and global maximal dose were improved from 3.2, 0.08, 77.4 Gy with DS to 2.8, 0.04 and 72.1 
Gy with PBS. All differences are statistically significant, with p values <0.05, with the exception of the heart V45 (p= 0.146). 
PBS with BSPTV achieves better organ sparing and improves target coverage using a repainting method for the treatment of 
thoracic tumors. Incorporating motion-related uncertainties is essential in maintaining marginal coverage and homogenous 
dose of treatment targets.  
. 
 
Introduction 
 The variability and uncertainty in water equivalent thickness (WET) along the intended proton beam path within a 
patient can cause a target miss if not properly taken into account. Urie et al. proposed a correction strategy for the double 
scattering (DS) technique by minimizing compensator thickness over a smeared radius (i.e., the misaligned distance of the 
target), and extending the distal and proximal proton beam range by a percentage given by the uncertainty in converting CT 
Hounsfield units to stopping power. This “smearing” approach uses a perpendicular search radius, typically fixed at 5 mm, 
over the entire beam path to add treatment margin to the target along the beam path and was implemented in the treatment of 
thoracic tumors by Moyers et al. using the DS technique. In contrast to the implicit smearing embedded in the compensator 
design and direct manipulation of the distal and proximal ranges of DS beams, Park et al. introduced a beam specific PTV 
(BSPTV) initially proposed by Rietzel and Bert to explicitly include variation of water equivalent path length (WEPL) along 
each beam direction; in this manner the BSPTV can be used in pencil beam scanning (PBS) planning single field 
optimization (SFO).  In the BSPTV method (Rietzel and Bert, and Park et al), distal and proximal water equivalent treatment 
margins (WETM) are converted to geometric treatment margins (GTM) that are calculated according to local tissue 
heterogeneity and added beyond the target to achieve a smearing effect in PBS, thus accounting for WET variations related to 
the fixed value of misalignment of tissue from motion and setup. 
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 Neither Moyer’s nor Park’s approaches account for the fact that the magnitude of motion varies within different 
anatomic regions. The modeling of treatment margin due to organ motion can be further improved by using Maximum 
Intensity Projections (MIP) and Minimum Intensity Projections (MinIP) obtained from 4DCT (Underberg et al). Matney et al. 
and Flampouri et al. used 4DCT for evaluation of robustness and for construction of a BSPTV in DS treatment plans, 
respectively.  
Respiratory motion patterns change among different segments of the thorax region (Keall et al.). The magnitude of 
motion at a patient’s surface (i.e., at the beam entrance) can be significantly smaller than that of tumor motion (Liu et al. and 
Weiss et al.). Therefore, a fixed smearing value based on the magnitude of target motion would typically be too large for 
proximal regions along the beam path, and a BSPTV using a fixed smearing radius corresponding to tumor motion magnitude 
would be larger than needed. Multiple researchers have attempted to refine the BSPTV method using 4DCT for PBS 
treatment. Graeff et al. attempted to extend BSPTV to multiple field optimization (MFO) IMPT fields in GSI’s in-house TPS. 
Knopf et al. calculated BSPTV as the union of multiple treatment targets (CTV + margins) over different phases of 4DCT 
using the PSI and NIRS in-house deformable registration algorithms.  
 PBS treatment planning for thoracic tumors can achieve better sparing of organs at risk (OAR) than IMRT 
techniques (Chang et al., Kang et al. and Zhang et al.). Despite the dosimetric advantages of PBS, DS and IMRT remain the 
methods of choice for treating complex thoracic tumors. This is primarily because commercial treatment planning systems 
(TPS) are unable to: (1) calculate proton spot delivery interplay with organ motion, which can lead to overdose and 
underdose within the treatment volume, and (2) determine appropriate treatment margins around the treatment target due to 
uncertainties of motion, stopping power and setup, which might result in partial anatomical miss or underdose of the target 
volume. Although Li et al. recently evaluated the systemic errors in 3D dose calculation that appear in the PBS treatment of 
thoracic tumors, there is no simultaneous comparisons of OAR sparing and plan robustness between PBS and DS treatments 
in this disease site (Wink et al.)  
In this work, we describe the development of a patient field-specific BSPTV, that incorporates respiratory motion 
and stopping power uncertainties using 4DCT for PBS treatment of thoracic tumors. As reported by previous researchers 
(Graeff et al. and Knopf et al.), we calculated the change of water equivalence path length (WEPL) associated with organ 
motion and converted such WETM to GTM based on local tissue densities. In contrast to the conceptual demonstration by 
Graeff et al. for MFO application, we focus on SFO application in multiple thoracic patients. And unlike Knopf et al., who 
conceptualize the method of using the union of (multiple deformable targets + treatment margins) over different breathing 
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phases in two different in-house TPS of PSI and NIRS, our treatment margin is applied to average CT images and the iCTV, 
which is the union of multiple CTV targets rigidly registered from eight phases in a commercially available TPS (Varian 
Eclipse, Palo Alto, CA).  Compared to Knopf and Graeff’s approach, we need only to calculate WETM and convert WETM 
to GTM once instead of eight or ten times (the # of breathing phases). This may lead to slightly larger target volumes than 
those of Knopf and Graeff, similar to the more generous margin calculation method proposed by Flampouri et al. for DS 
treatment. To illustrate the potential advantages of BSPTV using 4DCT for the treatment of thoracic tumors, we will 
demonstrate how such a method is equivalent to “flexible smearing” in DS and can generate a more appropriate treatment 
target volume for a typical patient.  
A number of pioneering researchers have demonstrated the magnitude of overdose and underdose within the target 
volume caused by PBS delivery interplay with organ motion and how such deviation from the prescribed dose distribution is 
washed out with multiple fractions (Dowdell et al., Grassberger et al., Ritchter et al. and Li et al.). In this study we 
demonstrate such an interplay phenomenon for a representative thoracic patient. 
The focus of this study is to establish a method of BSPTV calculation and organ interplay so that we can 
systemically report the dosimetric difference of PBS and DS treatment methods for ten thoracic tumor patients. Such methods 
and dosimetric studies can also serve as the platform and baseline for future improvements that can be brought by various 
motion mitigation strategies such as multiple beam paintings, gating and tracking techniques (Lomax et al.)  
  
Methods 
In conventional radiation therapy, the internal clinical target volume (iCTV) is delineated by a radiation oncologist 
and by the union of CTVs on the corresponding eight- or ten-phase images of a 4DCT on average CT images. To account for 
random and systematic errors of patient setup, an additional margin of 5-8 mm is used to expand an iCTV to a PTV.  
Our methodology to calculate WETM and convert WETM to GTM is based on the phase and average images of 
4DCT and implemented as a standalone MATLAB (MathWorks, MA) program. The generated BSPTV were imported into 
Eclipse TPS for subsequent optimization, thus providing better PBS treatment plan of thoracic tumors. Instead of using a 
“fixed smearing” distance to search for maximal WEPL change over a beam path, the maximal difference of WEPL between 
eight 4DCT phases and the average CT images was used as WETM along each beam path. The distal and proximal water 
equivalent margins (DMwe and PMwe) due to organ motion (WETM) were calculated as the WEPL difference between the 
MIP, MinIP and average of the eight phases of the 4DCT, respectively (Equations 1 and 2). In this manner, different 
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smearing radii along the beam path, i.e. “flexible smearing,” were effectively used to calculate WETM.  Such WETM were 
later implemented as additional voxels beyond treatment targets (i.e. GTM) based on the local Hounsfield units in the average 
CT images and the projected voxel size over the beam path, whose summation should equal to WEPL differences (Equations 
3 and 4). The steps of conversion of WETM to GTM were omitted in the original smearing approaches by Urie et al. and 
Moyers et al. but implemented in recent works of Rietzel, Park, Flampouri, Graeff and Knopf. Figure 1-(a) shows an example 
of how a fixed smearing of 5 mm radius over average CT images overestimates a BSPTV compared to that of flexible 
smearing over 4DCT images. Two BSPTVs, generated using fixed smearing and flexible smearing, are shown for a gantry 
angle of 270 degree. Because the motion of the ribs is less than that of the target, a fixed smearing of 5 mm radius 
overestimates the distal and proximal BSPTV margins. For the regions close to the heart, however, the distal BSPTV margin 
from flexible smearing can be slightly larger than that from fixed smearing because cardiac motion can exceeds 5 mm. In 
addition, cardiac motion is not inadequately modeled by breathing-phase-based 4DCT images. Figure 1-(b) demonstrates 
how the beam specific range uncertainties are broken down into three aspects: internal motion (Motion), stopping power ratio 
(SPR) of medium-to-water versus Hounsfield units in CT images, and the accuracy of image guidance (Setup). The BSPTV 
calculation uses 3% of the proton range plus 1 mm related to CT/stopping powers and, for patient setup variation, 2 mm 
along AP/RL directions and 3 mm along the SI direction. As these three sources of uncertainties are most likely independent, 
a quadratic method was primarily used for the summation of three uncertainties; however, a linear summation was also used 
to ensure target coverage, providing there was no overlap with adjacent organs at risk. Figure 1-(c) shows the contributions to 
the BSPTV as a function of gantry angle. The contribution from Motion is larger than from CT/SPR or Setup and contributes 
over 90% of the Sum as determined by the following equations: 
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where i are the voxels along the beamlet from the patient surface to the proximal and distal surfaces of iCTV in Equation 1 
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and 2, respectively; j are the amount of voxels to be determined in the distal and proximal GTM regions in Equation 3 and 4, 
respectively; and where l and dl are voxels and projected voxel dimension along the beam path in average CT, respectively. 
We further define two overlap volumes; one between the BSPTV and organs, and the other between the beam path 
outside of the BSPTV and organs. While the beam path overlap volume may receive less than the full prescription dose of 
66.6 Gy, minimizing the overlapped volumes along with the BSPTV will allow for sparing of lung, heart and cord prior to the 
step of plan optimization. Figure 1-(d) shows how the Matlab code generates an optimized BSPTV and overlapped volume at 
an ideal gantry angle. In this figure, a gantry angle of 300 degree was selected by both Matlab and the dosimetrist since it 
corresponded to the long axis of the target and optimal BSPTV and overlap volumes. In contrast, a gantry angle of 180 
degree chosen by the dosimetrist is suboptimal since the BSPTV and overlap volumes are both relatively large.  
Motion, CT/SPR, Setup, Quadratic and Linear Summations BSPTVs were used in the optimization step of PBS 
treatment planning for each of the 10 patients evaluated. The BSPTVs were optimized with goals of covering 99% of the 
target volume with 99% of the prescription dose of 66.6 Gy in 1.8 Gy (RBE) per fraction, though the coverage of BSPTV 
could be selectively compromised if there was a critical OAR constraint. The OAR constraints within the optimizer were set 
according to the constraints used in the RTOG 1308 protocol, a phase III randomized trial comparing Photon Versus Proton 
chemoradiotherapy for inoperable stage II-IIIB NSCLC. Two fields were used in each PBS treatment plan, and each was 
individually optimized and summed at the last step without any further optimization. The treatment angles were kept the 
same in PBS plans as they were in DS plans unless the plan optimizer preferred other angles.  
Any comparison of treatment plans depends on the characteristics of beam lines used. The spot and Bragg peak 
characteristics of the IBA pencil beam scanning beam line have been reported by Farr et al., Grevellot et al. and Lin et al., 
while the source size and Bragg peaks of the double scattering technique have been described by Slopsema et al. The spot 
sigma at most patient surfaces decrease from 7 to 3 mm for proton energies from 100 to 225 MeV. In order to treat tumors 
shallower than 75 mm, i.e. the proton range of 100 MeV beams, we utilize a U-shaped bolus (Both et al.) with a WET of 75 
mm placed on the top and lateral sides of patient. Our proton couch also has a built-in bolus with a WET thickness of 65 (or 
75 mm with an overlay) to enable treatment of superficial posterior tumors. The dose algorithm PCS13.0.24 was used for all 
PBS and DS calculations of Eclipse TPS. The commissioning of Eclipse has previously been reported by Zhu et al.  
To facilitate plan comparison between PBS and DS techniques, several dosimetric indices of target iCTV were used 
in this work, as described by Flampouri et al.: the volume of 100% isodose line, IDL100%; the Heterogeneity index, HI=(D5%-
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D95%)/Dprescription; the Conformity index, CI=IDL100%/Vctv; Coverage quality, CQ=Dmin/ Dprescription; and Integral dose, 
ID=Vbody×Davg. 
Lomax et al. displayed uncertainty bands on the DVH curve to designate the uncertainties due to stopping power and 
patient setup. The uncertainty band method was also implemented by Lin et al. and Vargus et al. for OAR and target 
coverage for patient setup variation. In this work, a total of 8×12×10=960 plans were evaluated for ten patients, comprising 
permutations of eight 4DCT phases, ±3% stopping power, and ±3 mm x/y/z in patient setup. Percentiles of 25%-75% of all 
the permutations from the average DVH of OARs and iCTV were calculated for a representative patient and all ten patients 
(Figure 2 and Figure 3). The difference between PBS and DS was also calculated and displayed. 
Ten consecutive patients treated with DS for stage III locally advanced non-small cell lung cancer were selected for 
the evaluation of PBS plans. All patients had mediastinal nodal metastases with various primary tumor locations. The 
comparisons of DVH criteria were evaluated using a paired t-test for statistical significance. 
The method we used to evaluate beam interplay is similar to Zou et al. for conventional lung SBRT applications and 
other researchers for PBS applications (Grassberger et al., Dowdell et al., Graeff et al., Knopf et al. and Li et al.). A 
representative patient is shown in Figure 4, with a breathing period of ~3.5 seconds and delivery durations of ~60 seconds 
and ~46 seconds for the two beams. Switching time between energy layers, slew duration between spots and spot duration of 
the same energy layer were extracted from the beam delivery log files. For different treatment fractions or beam paintings 
within the same fraction, the beams start from a random position in the 3.5-second breathing period. PBS spots were 
therefore grouped into the eight different breathing phases. A single treatment plan was therefore split into eight plans outside 
of Eclipse using our in-house Matlab programs and a Dicom editor provided by Ion Beam Applications (Louvain-La-Neuve, 
Belgium). These plans were subsequently reimported into Eclipse TPS to calculate the dose distribution of each CT phase. 
The eight dose distributions were deformed and registered to the exhale-50 phase and summed in MIM Maestro (MIM 
Software Inc., Cleveland, OH).  
 
Results 
 Table 1-(a) shows the magnitude of motion at three locations along the beam path for the ten consecutive patients 
evaluated. Tumor motion was larger than that of the ribs or at the patients’ surface (beam entrance), and it was largest in the 
SI direction (~8 mm) followed by AP (~4 mm) and RL (~2 mm) directions. In contrast, the average motion of the ribs and 
patient surface at the beam entrance were less than 1.5 mm and 1 mm, respectively.  Out of ten patients, all of whom were 
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treated with two-field plans, six plans were treated using posterior and posterior oblique beams only, two plans involve a 
lateral beam, and the other two plans included an anterior beam. With supine positioning, there is minimal motion of ribs and 
posterior beam entrance. In contrast, when lateral or anterior beams were used, the motion was larger. Table 1-(b) shows 
BSPTV as a function of source of uncertainty.  In the summed BSPTV, motion-induced range uncertainties were the largest 
contribution to treatment margins.  
Figure 2 shows a representative patient treated with DS who would have benefited from a PBS technique.  PBS 
spared both the high and low dose regions and allows reduced doses to the lung, heart, cord and esophagus compared with 
DS technique, while still maintaining 99% dose coverage of 99% of the iCTV. Furthermore, dose inhomogeneity and 
hotspots within the target were minimized, whereas target coverage was maintained for both PBS and DS (within ~2% dose) 
when 4DCT, stopping power and patient setup uncertainties were incorporated.  
Figure 3-(a) shows the average, 25th and 75th percentile DVH bars for lung, heart, cord and esophagus of all ten 
patients for PBS (red) and DS (blue). P-values >0.05 suggest that the PBS advantage observed may not be statistically 
representative of each individual patient.  
PBS plans were superior to DS in all cases. The greatest improvements with PBS was primarily within the low (V5) 
to moderate (V10 and V20) dose regions, with a reduction in mean lung dose (MLD) by 2.3 Gy from 16.4 Gy with DS to 
14.1 Gy, and heart V30 from 10.4% to 8.1% with PBS (Table 2). There is a large variation in heart dose among the ten 
patients. Because one patient had almost no dose to the heart, the maximal heart dose average over ten patients fell outside of 
the 25 and 75 percentiles for both PBS and DS treatments. Excluding this patient, PBS had a maximal heart dose of 70.9 Gy 
averaged over nine patients, with 25 and 75 percentiles from 70.3 to 71.3 Gy, while DS had a maximal heart dose of 74.1 Gy 
averaged over nine patients, with 25 and 75 percentiles from 70.8 to 75.1 Gy. The reduction in heart V45, was not 
statistically significant (p=0.146).  
In keeping with the dose constraints from RTOG 1308, only the maximum dose was constrained for esophagus.  
Despite this, PBS still resulted in a reduction in the average volume of esophagus irradiated. A p value of 0.049 indicates that 
the Dmax for PBS can be larger than for DS for some patients, although this occurs only when Dmax is well below 74 Gy. 
Because one patient had a maximal esophagus dose of 48 Gy in PBS treatment, the average over 10 patients fell outside of 
the 25 and 75 percentiles. Excluding this patient, PBS had a maximal esophagus dose of 70.0 Gy averaged over nine patients, 
with 25 and 75 percentiles from 69.5 to 71.2 Gy, while DS had a maximal esophagus dose of 72.6 Gy, with 25 and 75 
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percentiles from 70.5 to 73.5 Gy. The reduction in maximum heart and esophageal dose for certain patients from 72 Gy to 68 
Gy (Table 2 and Figure 3) suggests that additional patients would benefit from PBS.  
Table 2 shows that the integral dose (ID) is reduced by nearly 17% in PBS compared with DS.  Additionally, the 
irradiated volume of the prescription dose (CI) is only reduced by 10%. The target coverage quality CQ is identical between 
PBS and DS, as 99% of the iCTV was required to receive the prescription dose with both techniques. In contrast, PBS results 
in a significantly more homogenous dose, with a homogeneity index HI of 0.04 compared with 0.08 for DS. Except for the 
marginal advantage of CI (p = 0.056), all the differences above were highly statically significant, with p <0.01. 
The robustness of iCTV coverage is shown in Fig. 3-(b) for all ten patients. For all PBS and DS plans, the iCTV 
receives no less than 97% of the prescription dose when all permutations of motion, CT/stopping power and patient setup 
uncertainties are included. Despite many clinical fears over overdose/underdose within the treatment target and target miss, it 
seems that PBS can potentially provide robust target coverage comparable or superior to that of DS when uncertainties are 
properly accounted for in the BSPTV with a repainting method to be discussed.  
 
Discussion 
 Flampouri et al. proposed two methods to improve BSPTV in DS over the approach of Park et al by incorporating 
respiratory motion using two methods. The first uses MIP and MinIP data from 4DCT to determine the distal and proximal 
margins, respectively. In the second, the 4DCT phase that generates the largest margins is selected for each beamlet (beam 
path) to the target. The beamlet method results in a smaller BSPTV than the MIP/MinIP method. Unlike DS, however, in 
which all energy layers are delivered within 0.1 seconds, PBS delivers different energy layers sequentially over minutes. 
Thus delivery of the distal and proximal layers are out of phase and, in contrast with DS, more generous margins must be 
determined from MIP/MinIP instead of the worst 4DCT phase in PBS. We demonstrated that the contribution from motion is 
the dominant effect over stopping power and setup uncertainties to the treatment margins in PBS and concluded that “flexible 
smearing” based on MIP/MinIP is crucial to the success of PBS plan optimization. We further included the overlapped 
volumes of beam path with organs. Unlike DS, which always over treats proximal organs, sparing of such OARs by PBS 
beam can be substantial.  
Our finding that the iCTV is more homogenously covered in PBS than in DS does not account for organ interplay 
with beam delivery in PBS.  Accounting for interplay, the target dose distribution in each of 37 fractions of PBS is more 
heterogeneous than the planned distribution. The breathing period of ~3.5 second is comparable with the switching time 
 10 / 20 
 
between energy layers (1-2 seconds for our PBS system) and also comparable with the time required to paint each energy 
layer (with 3-5 ms per spot and 2-4 ms slew duration between adjacent spots with a total of ~6000 spots over ~20 energy 
layers). Our study indicates that an energy layer can be delivered in 1-4 out of 8 different breathing CT phases of different 
breathing cycles. As our spot size is relatively small, more fractions might be needed to achieve total dose homogeneity 
compared with centers employing larger spot sizes. Figure 4 shows the interplay on an axial slice: underdose (95%) and 
overdose (110%) are present for a single fraction without any motion mitigation. As a worst case scenario, dose 
heterogeneities from 90-120% can occur in a single fraction. However, such a magnitude of overdose and underdose within 
the target will be reduced when more treatment fractions are used. With 4 fractions, the extent of such overdose drops to 
105%, with no 95% underdose, and with 8 fractions the 105% overdose volume decreases even further. The summated 
distribution from the deformable registered dose distributions of four fractions accounting interplay has a slightly larger area 
of 105% isodose and slightly smaller minimal dose than the planned dose distribution. With eight fractions, there was no 
observable difference for the DVH of the iCTV that accounted for interplay and the original treatment plan without interplay. 
As multiple beam paintings of 4 are clinically achievable, we believe that the dosimetric advantage of PBS treatment in this 
patient will be able to be maintained despite the interplay phenomenon. These observations are consistent with that reported 
by many researchers (Rietzel et al., Grassberger et al., Dowdell et al., Li et al. and Ritcher et al.). Because the breathing 
period and beam duration can vary from patient to patient, detailed assessment of the interplay effect for multiple patients and 
multiple motion mitigation strategies is the subject of current investigation within our group. Interplay is not an issue in DS, 
since all energy layers are painted every 0.1s. 
 Any plan comparison between PBS and DS techniques depends on the spot size of the PBS system, the placement of 
bolus/range shifter, the source size of the DS system, and the choice of prescription dose. The in-air proton spot size of our 
beam lines is smaller than those of the Hitachi system reported by Gillin et al. Furthermore, because the built-in posterior 
bolus and U-shaped anterior and lateral bolus are closer to the patient surface than range shifters mounted on the PBS nozzle, 
the spot size incident on the patient is smaller than systems that use nozzle-mounted range shifters. Therefore, conclusions 
drawn from this study may not be applicable to other beam lines.  
 
Conclusion 
 The use of a beam-specific PTV based on respiratory motion along the beam path derived from 4DCT and 
incorporating CT/stopping power and patient setup uncertainties can achieve better organ sparing with PBS compared to DS. 
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Additionally, our study indicates that PBS planning based on BSPTV method can potentially achieve both better target 
homogeneity and robustness of target coverage using a repainting delivery method. Finally, beam angle optimization 
provides a reliable method to minimize doses to the critical organs. 
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Figure 1: (a) Two axial slices of BSPTVs were generated based on flexible smearing over 4DCT images versus 5 mm fixed 
smearing over average CT images at a gantry angle of 270 degree. The red, green and yellow contours are iCTV, BSPTVs 
from flexible smearing and fixed smearing, respectively; (b) A single axial slice showing BSPTV for another gantry angle of 
300 degree with components originating from uncertainties in patient setup (Setup), CT/stopping power ratio conversion 
(SPR), 4DCT motion (Motion) and their linear and quadratic summations; (c) BSPTV volumes as a function of gantry angle 
with the quadratic ally and linearly summated BSPTV (QuaSum, LinSum); (d) Overlapped volumes of the BSPTV and beam 
path with lung, heart and cord are plotted as a function of gantry angle.  
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Figure 2: (a) Dose distribution and (b) DVHs for both DS (top, dashed lines) plans and PBS (bottom, solid lines) are 
displayed for a representative patient with locally advanced non-small cell lung cancer. 
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Figure 3: Average (solid lines) and 25th and 75th percentile (dashed lines) DVHs for PBS (red lines) and DS (blue lines) of (a) 
OAR and (b) iCTV of 10 patients with uncertainties of 3 mm setup and 3% stopping power ratio (SPR). 
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Figure 4: Beam interplay with organ motion for a representative patient with locally advanced non-small cell lung cancer. 
Dose distributions of one, four and eight treatment fractions are shown in top left, top right and bottom left, respectively. The 
bottom right shows the DVH of iCTV for one, four and eight treatment fractions accounting for interplay and original 
treatment plan without accounting interplay. Dark red, red, yellow, magenta and green contours represent the isodose lines of 
110%, 105%, 100%, 95% and 50% of the prescription dose. 
 
 
 
 
 
 20 / 20 
 
Table.1. (a) Magnitude of motion in mm observed along the beam path for the target, rib and entrance; and (b) beam specific 
planning target volumes in cm3 due to CT/stopping power ratio, motion,  and patient setup uncertainties, the quadratic and 
linear summations of three uncertainties for twenty beams of ten patients. 
(a) 
 Target  Rib  Entrance 
  Mean ± SE  Mean ± SE  Mean ± SE 
Superior-Inferior (SI)  8.3 ± 2.2  1.4 ± 1.2  0.7 ± 1.6 
Anterior-Posterior (AP)  3.7 ± 1.2  1.3 ± 1.0  0.8 ± 1.7 
Right-Left (RL)  2.4 ± 1.0  1.2 ±1.0  0.5 ± 1.0 
 
(b) 
 iCTV  CT  Motion  Setup  Quadratic S  Linear S 
 Mean ± SE  Mean ± SE  Mean ± SE  Mean ± SE  Mean ± SE  Mean ± SE 
Volume 243 ±131  506 ± 185  633 ± 203  482 ± 186  656 ±  207  755 ±  218 
 
 
 
 
Table 2: Comparison of OAR dose-volume criteria, OAR maximum dose, and target coverage for PBS and DS plans in ten 
patients.  
 DS  PBS  Difference (DS-PBS) 
 Mean [25th~75th]  Mean  [25th~75th]  Mean  [25th~75th] p-value 
Lung          
  V5 (%) 35.0 [28.7~41.4]  30.7 [24.4~37.0]  4.3 [2.8~5.5] 0.003 
  V20 (%) 29.0 [21.7~34.4]  24.6 [18.8~30.7]  4.4 [1.9~6.6] 0.001 
  Mean dose (Gy) 16.4 [11.7~19.7]  14.1 [10.5~17.2]  2.3 [1.4~3.2] <0.001 
Heart          
  V30 (%) 10.5 [4.8~14.8]  8.2 [1.8~11.5]  2.3 [1.1~3.3] 0.004 
  V45 (%) 7.5 [2.9~11.2]  5.5 [0.9~7.7]  2.0 [0.9~3.4] 0.146 
Max dose           
  iCTV (Gy) 77.2 [75.1~79.1]  72.3 [71.6~72.9]  5.0 [3.1~6.5] <0.001 
  Cord (Gy) 37.2 [34.8~45.4]  31.9 [28.0~42.2]  5.3 [1.2~7.3] 0.012 
  Esophagus (Gy) 71.6 [69.3~73.4]  67.8 [69.4~71.1]  3.7 [0.7~4.1] 0.049 
  Heart (Gy) 69.1 [71.7~75.4]  64.7 [70.2~71.3]  4.5 [1.5~5.0] 0.016 
Criteria          
      ID(GyL) 1.30  [0.87~1.67]  1.10 [0.78~1.32]  0.2 [0.08~0.34] 0.002 
      CI 3.2 [2.3~3.7]  2.8 [2.1~3.4]  0.4 [-0.06~0.75] 0.056 
      CQ 0.99 [0.99~1.00]  1.00 [1.00~1.00]  -0.01 [-0.01~0.00] 0.007 
      HI 0.08 [0.06~ 0.09]  0.04 [0.04~ 0.04]  0.04 [0.03~0.05] <0.001 
 
